PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma
PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.
Why AvenCell Therapeutics is using AVC-203 to test whether allogeneic CAR-T can move beyond manufacturing bottlenecks
AvenCell Therapeutics has dosed the first AVC-203 patient in QUADvance. Read what this means for allogeneic CAR-T and B-cell cancer treatment.
How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.